Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pablo Borrega Garcia"'
Publikováno v:
Melanoma Research. 31:268-271
The emerging role of BRAF and MEK tyrosine-kinase inhibitors has shown new opportunities of treatment for patients with advanced melanoma and BRAF mutations. Its use is associated with some toxicities, as pyrexia, that clinicians may not be familiari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c938f68098263f39fc0411bb868d6e
https://doi.org/10.1097/cmr.0000000000000733
https://doi.org/10.1097/cmr.0000000000000733
Autor:
Juan Manuel Praena-Fernández, Pablo Ayala de Miguel, Jon Cacicedo, Pablo Borrega Garcia, Jose Luis Lopez Guerra, Blas David Delgado, Eleonor Rivin del Campo, Laura Quintana Cortés, María Valle Enguix-Riego, Marco Perez
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background] Small cell lung cancer (SCLC) is one of the greatest therapeutic challenges of oncology. Potential associations between single nucleotide polymorphisms in heat shock protein β1 (HSPB1) and transforming growth factor β1 (TGFβ1) and sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216b0287904fd04fc1686c2c6d7ab7c9
http://hdl.handle.net/10261/266654
http://hdl.handle.net/10261/266654
Autor:
Itziar Gorospe García, Pablo Ayala de Miguel, Andrea Posada Restrepo, Alfonso Acero Caballero, Eduardo Ceballos Barbancho, José Manuel Rodríguez García, Rubén Alonso Calderón, Pablo René Rivera Vargas, Andrea Illán Varella, Jonathan Aires Machado, Javier Gallego, Laura Quintana Cortés, Pablo Borrega Garcia
Publikováno v:
Journal of Clinical Oncology. 38:e21662-e21662
e21662 Background: Immunotherapy of cancer has changed the paradigm of treatment of many tumours, specially non-small cell lung cancer (NSCLC). The use of immune-checkpoint inhibitors (ICI) is associated in some patients with the development of new i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baad6806ea83405bf473acdccf30e84f
https://doi.org/10.1200/jco.2020.38.15_suppl.e21662
https://doi.org/10.1200/jco.2020.38.15_suppl.e21662
Autor:
Rubén Alonso Calderón, Pablo Borrega Garcia, Pablo Ayala de Miguel, Eduardo Ceballos, Itziar Gorospe García, Andrea Posada Restrepo, Pablo René Rivera Vargas, José Manuel Rodríguez García, Alfonso Acero Caballero, Jonathan Aires Machado, Laura Quintana Cortés, Javier Gallego, Andrea Illán Varella
Publikováno v:
Journal of Clinical Oncology. 38:e21664-e21664
e21664 Background: Hyperprogressive disease (HPD) is a new pattern of progressión during immunotherapy and is described as an acceleration of tumor growth during treatment with immune checkpoint inhibitors (ICI). The rate of HPD in advanced solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::203df8d975b1fc103511735df1f19fb0
https://doi.org/10.1200/jco.2020.38.15_suppl.e21664
https://doi.org/10.1200/jco.2020.38.15_suppl.e21664